Clinical trials: Asthma Patients
Airway Obstruction, Asthma
Effects of Combined Respiratory Muscle Training and Steam Inhalation
The purpose of this investigation is to obtain more information on the efficacy and safety of respiratory training methods with WellO2 in patients with asthma and COPD.
- Conditions
- Airway Obstruction, Asthma, COPD
- Trial name
- NCT04584398
- Testing
- Respiratory muscle training with steam inhalation
- Where
- Finland
- Volunteers
- 60 people
- Sponsor
- WellO2 Oy
Asthma
A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Uncontrolled Severe Asthma
This is a Phase IIb, randomized, placebo-controlled, double-blind, multicenter, multi-arm study which will evaluate efficacy, safety, and pharmacokinetic of MSTT1041A compared with placebo as add-on therapy in participants with…
- Trial name
- NCT02918019
- Testing
- MSTT1041A
- Where
- 138 sites in United States, Argentina and 13 more
- Volunteers
- 517 people
- Sponsor
- Hoffmann-La Roche
Asthma
Safety and Efficacy of WIN-901X in Asthma
This clinical trial is designed to evaluate the efficacy, dose-response and safety of WIN-901X in Asthma patients.
- Trial name
- NCT01820481
- Testing
- WIN-901X dose level 1, WIN-901X dose level 2, WIN-901X dose level 3
- Where
- South Korea
- Volunteers
- 209 people
- Sponsor
- Whanin Pharmaceutical Company
Asthma
The Effect of MK0633 in Patients With Chronic Asthma (0633-007)
A clinical study to evaluate the efficacy and safety of MK0633 in adult patients with chronic asthma.
- Trial name
- NCT00404313
- Testing
- MK0633
- Volunteers
- 688 people
- Sponsor
- Merck Sharp & Dohme LLC
Asthma
A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of AZD9898
In this integrated, multi-part, Phase I study, the safety, tolerability, food effect, pharmacokinetic (PK) and pharmacodynamic (PD) properties of single and repeated doses of AZD9898 will be investigated.
- Trial name
- NCT03140072
- Testing
- AZD9898
- Where
- 2 sites in United Kingdom
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Asthma
Efficacy and Safety Study of Fluticasone/Salmeterol Administered With Elpenhaler
The aim of this study is to establish the therapeutic equivalence between the test (Fluticasone/Salmeterol administered with Elpenhaler®db, Rolenium®) and the reference formulation (Seretide®, administered with Diskus®), both…
- Trial name
- NCT05459194
- Testing
- RP - TA
- Volunteers
- 42 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Asthma
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
This study assessed the effect on asthma control of different dose levels and regimens of QGE031 in asthma patients that are inadequately controlled with inhaled steroid and beta-2 agonist medication. Safety was assessed also.
- Trial name
- NCT01716754
- Testing
- QGE031, Omalizumab
- Where
- 150 sites in United States, Argentina and 22 more
- Volunteers
- 471 people
- Sponsor
- Novartis Pharmaceuticals
Children
Monitoring of Allergic and Asthmatic Symptoms in Patients Taking Dietary Supplements Joalis Bambi Bronchi and Joalis Bambi Analerg
Reduction of the total IgE antibody, improved vital capacity and lung volume measured by spirometry. Improving quality of life observed in the visual analogue scale (VAS).
- Trial name
- NCT01684137
- Testing
- Joalis Bambi Analerg, Joalis Bambi Bronchi
- Where
- Czechia
- Volunteers
- 100 people
- Sponsor
- DSC Services, s.r.o.
ASTHMA
A Multicentre, Prospective, Non-interventional Trial Monitoring Therapy Pathways of Asthma Patients Treated With an Extra-fine ICS/LABA/LAMA Single-inhaler Triple Therapy in a Real-world Setting and Characterizing the Effects on Health-related Outcomes
TriMaximize, a non-interventional trial aims to collect prospective, longitudinal data from asthma patients under routine care, for whom their treating physician has decided to prescribe Trimbow®…
- Trial name
- NCT05728749
- Testing
- Non-interventional
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Chiesi SAS
Severe Asthma
PROPE Severe Asthma Study in Egypt
Asthma is a syndrome characterized by airway inflammation, reversible airway obstruction, and airway hyper-responsiveness. Patients present clinically with recurrent wheezing, shortness of breath, cough, and chest tightness.
- Trial name
- NCT06283290
- Where
- 4 sites in Egypt
- Volunteers
- 201 people
- Sponsor
- AstraZeneca
Asthma
Efficacy and Tolerability of Beclometasone/Formoterol Single Inhaler in Patients With Moderate to Severe Persistent Asthma
Efficacy and tolerability of the fixed combination beclometasone/formoterol in patients with moderate to severe persistent asthma.
- Trial name
- NCT00476268
- Testing
- beclomethasone/formoterol (100/6µg) pMDI, Beclometasone dipropionate 250 µg/unit dose pMDI, Formoterol powder 12 µg/unit dose
- Volunteers
- 824 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma I
The aim of this trial is to evaluate the efficacy and safety of 2.5 and 5 mcg tiotropium over a 24-week treatment period as compared to placebo and salmeterol (50 mcg twice daily).
- Trial name
- NCT01172808
- Testing
- tiotropium Respimat® low dose, tiotropium Respimat® high dose, 50 mcg salmeterol HFA MDI
- Where
- 114 sites in United States, Brazil and 9 more
- Volunteers
- 1,071 people
- Sponsor
- Boehringer Ingelheim
Asthma
A Study to Evaluate the Safety and Tolerability of Multiple Dose of IBI3002 in Healthy and Asthmatic Participants
This study is a randomized, double-blind, placebo-controlled multiple dose ascending study in healthy participants and patients with asthma. Healthy participants will be enrolled in Part A and patients with asthma in Part B: 1.
- Trial name
- NCT06947408
- Testing
- IBI3002
- Where
- China
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Asthma
Next DPI LABA, Multicentre, 5-way Cross-over, Adult Asthmatic Patients
Multinational, multicentre, randomised, double blind, double dummy, placebo and active controlled, 5-way cross over
- Trial name
- NCT00868023
- Testing
- CHF 1535 Next DPI, Foster BDP/Formoterol
- Where
- United Kingdom
- Volunteers
- 69 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Pulmonary Disease, Chronic Obstructive
An Investigation Of The Interaction Of GSK961081 With Inhaled Beta-Agonist And Anti-Muscarinic Drugs.
GSK961081 is a potent dual pharmacophore that demonstrates both antimuscarinic and beta-agonist pharmacology in preclinical studies, both pharmacologies being of long duration.
- Trial name
- NCT00674817
- Testing
- 400 microgrammes GSK961081, 1200 microgrammes GSK961081
- Where
- 4 sites in New Zealand, Thailand and 1 more
- Volunteers
- 45 people
- Sponsor
- Theravance Biopharma
Respiratory Hypersensitivity
Safety and Efficacy of House Dust Mite Allergoid in the Treatment of Bronchial Asthma
The trial is performed to assess efficacy and safety of the Allergopharma house dust mite allergoid in bronchial asthma.
- Trial name
- NCT00263640
- Testing
- Acaroid
- Where
- Germany
- Volunteers
- 130 people
- Sponsor
- Allergopharma GmbH & Co. KG
Rhinitis, Allergic, Rhinoconjunctivitis
Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites
A double-blinded, placebo-controlled, prospective, multicenter randomized of 2 active treatment groups, compared to 1 placebo group, for the determination of the efficacy and safety of subcutaneous immunotherapy in patients with…
- Conditions
- Rhinitis, Allergic, Rhinoconjunctivitis, Asthma, Allergic
- Trial name
- MM09-SIT-023 (NCT04435990)
- Testing
- 10,000 MM09, 30,000 MM09
- Where
- 32 sites in Spain
- Volunteers
- 150 people
- Sponsor
- Inmunotek S.L.
Asthma
Effect of Inhaled Ciclesonide in Adult Patients With Asthma (BY9010/M1-125)
Ciclesonide is a novel inhaled corticosteroid for the treatment of asthma. In this study the effect of ciclesonide on airway hyperresponsiveness (AHR), exhaled nitric oxide (NO), and induced sputum inflammatory biomarkers will be…
- Trial name
- NCT00546520
- Testing
- Ciclesonide
- Where
- United Kingdom
- Volunteers
- 21 people
- Sponsor
- AstraZeneca
Asthma
Long-term Safety Study of QGE031 in Patients With Allergic Asthma Who Completed Study CQGE031B2201
This study planned to assess long-term safety of QGE031 during 12 months treatment in asthma patients who completed study CQGE031B2201.
- Trial name
- NCT02075008
- Testing
- QGE031
- Where
- 84 sites in United States, Argentina and 18 more
- Volunteers
- 270 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
A Compassionate Access Protocol to Assess the Safety of XolairTM (Omalizumab) in Patients (≥ 6 Years Old) With Severe Allergic Asthma Who Remain Symptomatic Despite Optimal Therapy
This study has the objective of providing compassionate use access to omalizumab (Xolair) and to evaluate the Safety of Xolair in subjects with severe allergic asthma who remain symptomatic despite optimal therapy according to…
- Trial name
- NCT00639691
- Testing
- omalizumab
- Where
- Canada
- Volunteers
- 48 people
- Sponsor
- Novartis